Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
Team-NB has published a position paper detailing how IVD Notified Bodies will manage the down-classification of SARS-CoV-2 tests following the MDCG...
The European Medicines Agency (EMA) has published three-year work plans for five working groups: Biosimilars, Biologics, joint CHMP/CVMP Quality,...
The Council of the EU and the European Parliament have reached a provisional agreement on reforming the EU’s pharmaceutical framework, focusing on...
This week's edition of Life Sciences weekly highlights includes analyses of the European Commission’s published Digital Omnibus on AI Regulation...
The European Commission has published a draft implementing regulation establishing the operational framework for the European Health Data Space (EHDS)...
Agriculture/Food—EU Regulatory trackerThis Practice Note tracks and summarises EU regulatory legislation guidance and other ongoing policy...
DeedsUnder English law, legally binding agreements can be made orally, in writing or by deed.This Practice Notice considers the circumstances in which...
Image rights—protection, exploitation and taxationFORTHCOMING CHANGE: it was announced at Budget 2025 that the government will legislate in Finance...
Joint, several, and joint and several liabilityContractWhere a contract is made by two or more parties it may contain a promise or obligation made by...
Supplementary protection certificates and paediatric extensions—UKThis Practice Note provides an introduction to supplementary protection certificates...
Template agreement—mutualThis Agreement is made on [date]Parties1[insert name of Party A][ of OR a company incorporated in [England and Wales] under...
IP evaluation and option agreement—pro-licensorThis Agreement is made on [insert date]Parties1[insert licensor name] [of OR a [company OR partnership...
IP evaluation and option agreement—pro-licenseeThis Agreement is made on [insert date]Parties1[insert licensor name] [of OR a [company OR partnership...
Patent assignment—pro-assigneeThis DEED is dated [insert date]Parties1[insert name] [of OR a company incorporated in [England and Wales] under number...
Patent assignment—pro-assignorThis AGREEMENT is dated [insert date]Parties1[insert name] [of OR a company incorporated in [England and Wales] under...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
An investigation conducted in human subjects which aims to discover or verify the effects of and adverse reactions to a medicinal product, ie, it assesses a medicine’s efficacy and safety.
Refers to the data exclusivity period granted by Article 10(1) of Directive 2001/83/EC, in which pre-clinical and clinical trial data generated and used to support the authorisation of an innovative medicinal product cannot be referred to by an applicant for a marketing authorisation for a generic product.
Unlicensed medicinal products for human use which have been specially manufactured or imported to the order of a doctor, dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber for the treatment of individual patients in order to fulfil the special needs of an individual patient.